Desoxycorticosterone

Brand names: Zycortal ยท Active ingredient: Desoxycorticosterone Pivalate

LabelDechra Veterinary Products
Label updatedJul 31, 2023

โš  Boxed warning (FDA's strongest warning)

Use ZYCORTAL Suspension with caution in dogs with congestive heart disease, edema, severe renal disease or primary hepatic failure. Desoxycorticosterone pivalate may cause polyuria, polydipsia, increased blood volume, edema and cardiac enlargement. Excessive weight gain may indicate fluid retention secondary to sodium retention.

Do not use desoxycorticosterone pivalate in pregnant dogs.

Desoxycorticosterone dosage

Prior to each use, thoroughly shake the vial to resuspend the product.

ZYCORTAL Suspension replaces the mineralocorticoid hormones only. Dogs with combined glucocorticoid and mineralocorticoid deficiency should also be treated with prednisone or prednisolone at an initial dosage of 0.2-0.4 mg/kg/day (0.1-0.2 mg/lb/day).

ZYCORTAL Suspension is intended for long-term administration at intervals and doses dependent upon individual response. Tailor the dose of ZYCORTAL Suspension and the concurrently administered glucocorticoid replacement therapy to the individual dog based on clinical response and normalization of Na+ and K+ concentrations.

The initial dose is 2.2 mg/kg (1 mg/lb) body weight, administered by subcutaneous injection.

Re-evaluate the dog and measure the serum sodium/potassium ratio (Na+/K+ ratio) approximately 10 days after the first dose, which is the time to maximum concentration (Tmax) of desoxycorticosterone . If the dog's clinical signs have worsened or not resolved, adjust the dose of prednisone/prednisolone and/or investigate other causes of the clinical signs.

At approximately 25 days after the first dose, re-evaluate the dog and repeat the Na+/K+ ratio.

If the dog is both clinically normal and has a normal Na+/K+ ratio on Day 25, adjust the dose based on the Day 10 Na+/K+ ratio using the guidelines in Table 1, below.

If the dog is clinically normal and has a Na+/K+ ratio > 32 on Day 25, either adjust the dose based on the Day 10 Na+/K+ ratio according to Table 1 or delay the dose .

If the dog is either not clinically normal or if the Na+/K+ ratio is abnormal on Day 25, adjust the dose of prednisone/prednisolone or ZYCORTAL Suspension .

If the Day 10 Na

+

/K

+

ratio is: | Do not administer Dose 2 on Day 10. | 25 days after the first dose, administer ZYCORTAL Suspension, as follows:

> 34 | Decrease dose to: 2.0 mg/kg

> 32 to 34 | Decrease dose to: 2.1 mg/kg

27 to 32 | Continue 2.2 mg/kg

24 to < 27 | Increase dose to: 2.3 mg/kg

< 24 | Increase dose to: 2.4 mg/kg

If the dog is clinically normal and the Day 25 Na+/K+ ratio is > 32, it is possible to prolong the dosing interval instead of adjusting the dose as described in Table 1. Evaluate the electrolytes every 3-7 days until the Na+/K+ ratio is < 32, and then administer 2.2 mg/kg of ZYCORTAL Suspension.

For subsequent doses, use the following guidelines if the dog is not clinically normal and/or has abnormal Na+ or K+ concentrations:

Clinical signs of polyuria/polydipsia: Decrease the prednisone/prednisolone dose first. If the polyuria/polydipsia persists, then decrease the dose of ZYCORTAL Suspension without changing the dosing interval.

Clinical signs of depression, lethargy, vomiting, diarrhea or weakness: Increase prednisone/prednisolone dose. โ€ฆ

Warnings & precautions

Do not take this medicine if: Do not use ZYCORTAL Suspension in dogs that have previously had a hypersensitivity reaction to desoxycorticosterone pivalate.

Not for human use. Keep this and all drugs out of the reach of children. Consult a physician in case of accidental human exposure.

Any dog presenting with severe hypovolemia, dehydration, pre-renal azotemia and inadequate tissue perfusion ("Addisonian crisis") must be rehydrated with intravenous fluid (saline) therapy before starting treatment with ZYCORTAL Suspension.

The effectiveness of ZYCORTAL Suspension may be reduced if potassium-sparing diuretics, such as spironolactone, are administered concurrently.

Desoxycorticosterone side effects

In controlled clinical field studies, one hundred fifty-two dogs were included in the field safety analysis. Adverse reactions are summarized in Table 2.

Adverse Reaction | ZYCORTAL Suspension(n = 113 dogs) | Active Control(n = 39 dogs)

Polyuria | 15.0% (17) | 12.8% (5)

Polydipsia | 13.3% (15) | 15.4% (6)

Depression/lethargy | 9.7% (11) | 2.6% (1)

Inappropriate urination | 8.0% (9) | 10.3% (4)

Alopecia | 5.3% (6) | 5.1% (2)

Decreased appetite/anorexia | 4.4% (5) | 2.6% (1)

Panting | 3.5% (4) | 0.0% (0)

Vomiting | 3.5% (4) | 0.0% (0)

Diarrhea | 2.7% (3) | 7.7% (3)

Shaking/trembling | 2.7% (3) | 2.6% (1)

Polyphagia | 1.8% (2) | 2.6% (1)

Urinary tract infection | 1.8% (2) | 0.0% (0)

Urinary incontinence | 0.9% (1) | 2.6% (1)

Restlessness | 0.9% (1) | 2.6% (1)

Urticaria/facial edema | 0.0% (0) | 5.1% (2)

One dog with a pre-existing Grade III/VI heart murmur developed congestive heart failure 17 days after the first administration of ZYCORTAL Suspension and was removed from the study.

About this medicine

Desoxycorticosterone pivalate is a mineralocorticoid hormone. Chemically, desoxycorticosterone pivalate is 21-(2,2-dimethyl-1-oxopropoxy)-pregn-4-ene-3,20-dione.

The structural formula is:

Molecular Formula: C26H38O4

ZYCORTAL Suspension is a white aqueous suspension. Each milliliter contains 25 mg of desoxycorticosterone pivalate. Inactive ingredients are 10.5 mg methylcellulose, 3 mg sodium carboxymethylcellulose, 1 mg polysorbate 60, 8 mg sodium chloride, 1 mg chlorocresol and water for injection (to 100%).

How it works: Desoxycorticosterone is a corticosteroid with primarily mineralocorticoid activity, similar to aldosterone. In the kidney, desoxycorticosterone causes sodium and chloride ion retention, and hydrogen and potassium ion excretion, creating an osmotic gradient. The osmotic gradient promotes water absorption from the renal tubules resulting in increased extracellular fluid volume, leading to blood volume expansion, improved venous return to the heart, and increased cardiac output.

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label โ€” it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 2c9b766a-c36b-44aa-bbd8-24fab24ca97c. Read the full official label on DailyMed.